| Literature DB >> 20540717 |
Angela Cánovas1, Raquel Quintanilla, Marcel Amills, Ramona N Pena.
Abstract
BACKGROUND: Selection for increasing intramuscular fat content would definitively improve the palatability and juiciness of pig meat as well as the sensorial and organoleptic properties of cured products. However, evidences obtained in human and model organisms suggest that high levels of intramuscular fat might alter muscle lipid and carbohydrate metabolism. We have analysed this issue by determining the transcriptomic profiles of Duroc pigs with divergent phenotypes for 13 fatness traits. The strong aptitude of Duroc pigs to have high levels of intramuscular fat makes them a valuable model to analyse the mechanisms that regulate muscle lipid metabolism, an issue with evident implications in the elucidation of the genetic basis of human metabolic diseases such as obesity and insulin resistance.Entities:
Mesh:
Year: 2010 PMID: 20540717 PMCID: PMC2894043 DOI: 10.1186/1471-2164-11-372
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Total population, HIGH and LOW group mean values ± standard error for the traits used in the selection index
| Weight in PC1† | Population | HIGH group | LOW group | ||||
|---|---|---|---|---|---|---|---|
| 0.218 | 122.08 | ± 0.74 | 127.30 | ± 1.94 | 111.94 | ± 2.66 | |
| 0.342 | 23.58 | ± 0.26 | 27.26 | ± 0.69 | 19.00 | ± 0.64 | |
| 0.200 | 38.31 | ± 0.60 | 47.43 | ± 1.84 | 32.49 | ± 1.71 | |
| 0.328 | 25.71 | ± 0.19 | 28.47 | ± 0.41 | 20.94 | ± 0.61 | |
| -0.265 | 40.86 | ± 0.24 | 38.26 | ± 0.79 | 45.94 | ± 0.71 | |
| 0.304 | 5.17 | ± 0.10 | 7.46 | ± 0.39 | 3.58 | ± 0.15 | |
| 0.276 | 36.46 | ± 0.10 | 38.55 | ± 0.25 | 34.65 | ± 0.21 | |
| -0.315 | 20.62 | ± 0.32 | 14.37 | ± 0.52 | 27.35 | ± 0.81 | |
| 0.275 | 42.92 | ± 0.27 | 47.08 | ± 0.45 | 38.00 | ± 0.80 | |
| 0.335 | 125.15 | ± 1.40 | 157.60 | ± 5.02 | 104.03 | ± 2.70 | |
| 0.285 | 51.66 | ± 0.54 | 61.63 | ± 1.27 | 43.26 | ± 1.60 | |
| 0.266 | 63.12 | ± 1.09 | 82.65 | ± 4.70 | 50.58 | ± 2.53 | |
| 0.101 | 51.37 | ± 1.25 | 66.43 | ± 4.46 | 47.66 | ± 4.75 | |
The weight of each trait in the first principal component (PC1) is also indicated.
PC1 - weight of each trait in the first principal component.
Figure 1Graphical plot of the first and second principal components summarising phenotypic variation in the Duroc population. Summary of phenotype variation on serum lipid, growth and fatness parameters in the Duroc pig population. Relative weight of considered variables and position of animals from the HIGH and LOW groups are represented in the graph. Abbreviations are defined in Table 1.
Figure 2Functional categorisation analysis of the list of genes differentially expressed between the HIGH and LOW groups obtained with IPA. A: List of most significant pathways represented in the list of genes (p < 0.01). B: List of most significant networks affected by the joint effect of represented pathways (p < 0.01).
DAVID analysis of pathways significantly enriched in the list of differentially expressed genes
| KEGG id | KEGG pathway name | Genes (n) | Genes | Fold† | p-value* |
|---|---|---|---|---|---|
| ►01040 | Polyunsaturated fatty acids biosynthesis | 7 | 8.3046 | 0.00001 | |
| 05222 | Small cell lung cancer | 15 | 3.2728 | 0.0001 | |
| 04612 | Antigen processing and presentation | 12 | 2.8473 | 0.0027 | |
| 04510 | Focal adhesion | 21 | 2.0031 | 0.0034 | |
| ►04910 | Insulin signalling pathway | 15 | 2.1248 | 0.0097 | |
| ►03320 | PPAR signalling pathway | 9 | 2.3727 | 0.0334 | |
| ►04512 | ECM-receptor interaction | 10 | 2.1570 | 0.0396 | |
| ►04070 | Phosphatidylinositol signalling system | 9 | 2.2479 | 0.0444 | |
| 04150 | mTOR signalling pathway | 7 | 2.6054 | 0.0488 | |
| ►04930 | Type II diabetes mellitus | 6 | 2.5309 | 0.0844 | |
| ►04920 | Adipocytokine signalling pathway | 8 | 2.0802 | 0.0862 | |
| ►04350 | TGF-beta signalling pathway | 9 | 1.8982 | 0.0978 |
Fold enrichment of the KEGG pathways in the list of differentially expressed genes with regard to the background dataset; *p-value from Fisher's exact test. Arrows indicate pathways relevant to muscle/adipose tissue function.
Pathway Express analysis of metabolic pathways and gene networks significantly affected by differentially expressed genes
| KEGG pathway-id | KEGG pathway name | IF† | input/pathway genes | pathway genes on chip | p-value* |
|---|---|---|---|---|---|
| 04612 | Antigen processing and presentation | 61.066 | 15/88 | 45 | 1.87E-25 |
| ►04070 | Phosphatidylinositol signalling system | 18.350 | 10/77 | 60 | 2.08E-07 |
| ►01040 | Biosynthesis of unsaturated fatty acids | 10.791 | 7/23 | 18 | 2.43E-04 |
| 05222 | Small cell lung cancer | 8.686 | 14/87 | 71 | 1.64E-03 |
| 04510 | Focal adhesion | 7.117 | 20/199 | 169 | 6.58E-03 |
| 05332 | Graft-versus-host disease | 6.966 | 6/42 | 22 | 7.52E-03 |
| ►04910 | Insulin signalling pathway | 6.430 | 16/138 | 114 | 1.20E-02 |
| 05310 | Asthma | 6.323 | 5/30 | 17 | 1.31E-02 |
| 04520 | Adherents junction | 5.957 | 6/75 | 69 | 1.80E-02 |
| 04514 | Cell adhesion molecules (CAMs) | 5.952 | 13/133 | 95 | 1.81E-02 |
| 05330 | Allograft rejection | 5.813 | 6/38 | 26 | 2.04E-02 |
| ►04930 | Type II diabetes mellitus | 5.556 | 6/44 | 33 | 2.53E-02 |
| ►04512 | ECM-receptor interaction | 5.211 | 10/87 | 72 | 3.39E-02 |
| 05320 | Autoimmune thyroid disease | 4.955 | 6/53 | 31 | 4.20E-02 |
| 04940 | Type I diabetes mellitus | 4.955 | 6/44 | 31 | 4.20E-02 |
| 04150 | mTOR signalling pathway | 4.932 | 7/51 | 42 | 4.28E-02 |
| ►04920 | Adipocytokine signalling pathway | 4.779 | 8/72 | 64 | 4.66E-02 |
| ►03320 | PPAR signalling pathway | 4.684 | 9/69 | 61 | 4.75E-02 |
| ►04350 | TGF-beta signalling pathway | 4.662 | 9/89 | 74 | 4.95E-02 |
Impact Factor; *p-value from Fisher's exact test. Arrows indicate pathways relevant to muscle/adipose tissue function.
Validation of microarray expression data by quantitative real-time PCR for 25 selected genes
| GENE | MICROARRAY | qPCR | Correlation | ||||
|---|---|---|---|---|---|---|---|
| n = 68(34H | n = 20(10H | ||||||
| Ratio† | p-value | Ratio† | p-value | r* | p-value | ||
| ↑ | |||||||
| ADIPOR2 | ↑ | 1.39 | 0.001 | 1.49 | 0.354 | 0.59 | 0.0108 |
| ↓ | |||||||
| ↑ | |||||||
| CEBPD | ↑ | 1.24 | 0.004 | 1.05 | 0.078 | 0.69 | 0.0016 |
| ↑ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| ↓ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| ↓ | |||||||
| ↑ | |||||||
| ↑ | |||||||
| PPARGC1A | ↑ | 2.38 | 0.004 | 1.57 | 0.152 | 0.96 | < 0.0001 |
| RXRG | ↓ | 0.68 | 0.002 | 1.12 | 0.621 | -0.26 | 0.2911 |
| SCD | ↑ | 3.07 | 0.004 | 4.04 | 0.156 | 0.96 | < 0.0001 |
| TBC1D1 | ↑ | 1.17 | 0.0002 | 0.98 | 0.552 | -0.16 | 0.5287 |
| ↑ | |||||||
Expression ratios and p-values are indicated for both assays and correlation coefficients between qPCR and microarray results are also shown.
H = HIGH group; L = LOW group; Expression ratios between H and L groups; *correlation coefficients between qPCR and microarray results; in bold, genes whose difference in expression between groups has been validated by qPCR. Arrows up and down indicate gene overexpression and downregulation in the HIGH group, respectively.
Figure 3Comparison of microarray and qPCR expression ratios (HIGH vs LOW groups) for the list of selected genes.